Pazopanib: An Anti-Cancer MedicationCreated 1 month ago by marykudro
Pazopanib is an anti-cancer drug and has been approved for renal cell carcinoma and soft tissue sarcoma by multiple regulatory administrations worldwide. Pazopanib dosage as 800 mg orally once a day administered without food (at least 1 hour before or 2 hours after a meal). This medication comes with the strengths of 200 mg and 400 mg in the form of tablets. Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor that is involved in blocking the growth of tumours and inhibiting angiogenesis.